

Information For the User
Dapagliflozin (10mg) + Glimepiride (2mg) + Metformin (500mg) Tablet

Dapoflit GM 2/500 Tablet

Brand Name: Dapoflit GM 2/500 Tablet

Dosage Form: Tablet

Composition:

Each film-coated tablet contains:

- Dapagliflozin IP 10 mg
- Glimepiride IP 2 mg
- Metformin Hydrochloride IP 500 mg

Description:

Dapoflit GM 2/500 Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor; Glimepiride, a sulfonylurea; and Metformin, a biguanide antidiabetic agent. It is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled on dual therapy. It helps in improving glycemic control through complementary mechanisms of action while reducing fasting and post-prandial blood glucose levels.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on dual therapy with Dapagliflozin, Glimepiride, or Metformin

It helps in controlling fasting and post-prandial glucose levels and achieving overall glycemic stability.

Dosage & Administration:

Dosage should be as directed by the physician.

The tablet should be swallowed whole with water, preferably with meals to minimize gastrointestinal side effects.

Regular monitoring of blood glucose and renal function is recommended.

Pharmacological Action:

- **Dapagliflozin** inhibits SGLT2 in the renal proximal tubules, increasing urinary glucose excretion.
- **Glimepiride** stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner.
- **Metformin** decreases hepatic gluconeogenesis, improves insulin sensitivity, and reduces intestinal glucose absorption.

Together, these mechanisms provide synergistic glycemic control.

Side Effects:

Common side effects include gastrointestinal disturbances, increased urination, hypoglycemia (especially due to Glimepiride), genital infections, and mild dizziness.

Precautions & Warnings:

- Use with caution in patients with renal or hepatic impairment
- Monitor for hypoglycemia, particularly in elderly patients
- Risk of lactic acidosis with Metformin in predisposed individuals
- Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

Drug Interactions:

Concomitant use with insulin or insulin secretagogues may increase hypoglycemia risk. Caution with drugs affecting renal function or CYP450 metabolism.

Storage:

Store below 25°C in a cool, dry place.
Protect from light and moisture.
Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for